Continuing to innovate the main business of traditional Chinese medicine, the net profit of this pharmaceutical company increased by nearly 900% year-on-year

【Pharmaceutical Network Enterprise News】Fangsheng Pharmaceutical released the third quarterly report of 2022 on the evening of October 30, and the company's operating income in the reporting period was 484 million yuan, a year-on-year increase of 26.
43%; the net profit attributable to shareholders of listed companies was 196 million yuan, a year-on-year increase of 893.
16%; The net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses was 31.
6641 million yuan, a year-on-year increase of 66.
27%; Basic earnings per share were $
0.
45.
For the reasons for the growth of performance, the announcement said that the company focused on the main business, continued to optimize the business structure, while actively improving its research and development capabilities, deepened the reform of the marketing system, accelerated the adjustment of product structure, adhered to innovation-driven development, took the innovation and development of traditional Chinese medicine as the main body, and coordinated the promotion of the coordinated development of chemical drugs, achieving sustained and stable growth in business performance; From January to September 2022, the company effectively implemented the development strategy of "naturalization", and the pharmaceutical manufacturing industry performed well, with a year-on-year increase of 32.
76%
in revenue.
According to the data, Fangsheng Pharmaceutical is an enterprise mainly engaged in the research and development, production and sales of cardiovascular and cerebrovascular proprietary Chinese medicines, orthopedic and traumatic drugs, pediatric drugs, gynecological drugs, anti-infective drugs and other drugs, and the company is committed to building a health industry group with innovative Chinese medicine as the core, and driving the continuous improvement
of the company's core competitiveness with the two-wheel drive of "innovative Chinese medicine research and development" and "management change".
In recent years, Fangsheng Pharmaceutical has continued to focus on the main business of innovative traditional Chinese medicine, and has made great achievements in the research and development of innovative Chinese medicine drugs: from 2017 to January 2022, the NMPA approved a total of 21 traditional Chinese medicines, of which 2 were from Fangsheng Pharmaceutical
.
Following the "Pediatric Jingxing Cough Granules", Fangsheng Pharmaceutical's exclusive innovative Chinese medicine "Xuanqijian Bone Tablets" (registration classification: Chinese medicine class 1.
1) obtained the "Drug Registration Certificate"
in 2021.
At the same time, the company takes the "338 Project" with sales revenue of more than 100 million yuan as the product cluster goal, that is, to create 3 large products of 1 billion yuan, 3 large products of 500 million yuan and 8 products of more than 100 million yuan, continue to adjust marketing methods, and carry out various product promotion activities
in a professional and compliant manner.
According to the 2021 annual report, Fangsheng Pharmaceutical has successfully developed several brand series products
such as "Xinxuean" brand cardiovascular and cerebrovascular department, "Jinbeibei" brand pediatrics, "Meershu" brand gynecology, and "Fangshengtang" brand orthopedics.
It is also disclosed that since 2022, the sales of ezetimai tablets, strong loquat ointment (honey refining), strong loquat dew, children's Jingxing cough granules, Jinying capsules, dragon blood exhaustion, and blood plug (including blood plug dispersible tablets and blood plug tablets) under Fangsheng Pharmaceutical have increased significantly
.
The data shows that the sales of the above-mentioned core products of Fangsheng Pharmaceutical in the first three quarters of 2022 have exceeded the sales
of the whole year of 2021.
Among them, ezetimaib tablets have achieved sales revenue of nearly 200 million yuan, a year-on-year increase of nearly 100%, and the sales revenue of innovative Chinese medicine Pediatric Jingxing cough granules has increased by more than 100%
year-on-year.
Behind the continuous innovation, it is inseparable from the investment
of the company's research and development expenses.
The third quarterly report shows that the company's research and development expenses in the first three quarters were 48.
1436 million yuan, an increase of about 15.
1 million yuan over the same period of the previous year of 33.
041 million yuan
.
In addition to making efforts to innovate the main business of traditional Chinese medicine, the company has also optimized and adjusted its non-main business, and transferred chain medical companies and CRO companies in the body; And through entrusted production, transfer of major approvals and disposal of solidified assets, we actively improve the efficiency of the use of headquarters assets, give full play to the advantages of intensiveness, and continue to improve profitability
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.